Jorge Munoz-Muriedas

Title: Jorge Munoz-Muriedas: Innovator in P2X7 Modulation

Introduction

Jorge Munoz-Muriedas is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate P2X7 receptor function. With a total of 2 patents, his work focuses on addressing various pain-related disorders.

Latest Patents

Munoz-Muriedas's latest patents include innovative compounds such as 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives and 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives. These compounds are designed to modulate P2X7 receptor function and are believed to antagonize the effects of ATP at the P2X7 receptor. The applications of these inventions extend to the treatment and prophylaxis of inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis, and neurodegenerative disorders.

Career Highlights

Jorge Munoz-Muriedas is associated with Glaxo Group Limited, where he continues to contribute to innovative research and development in the pharmaceutical industry. His expertise in receptor modulation has positioned him as a key figure in the advancement of therapeutic solutions for pain management.

Collaborations

Throughout his career, Munoz-Muriedas has collaborated with esteemed colleagues such as David Kenneth Dean and Mairi Sime. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in their field.

Conclusion

Jorge Munoz-Muriedas exemplifies the spirit of innovation in pharmacology through his work on P2X7 modulators. His contributions are paving the way for new treatments that could significantly improve the quality of life for individuals suffering from various pain-related conditions.